Module

Journal Options Oncology: Hematologic Malignancies, Volume 1, Issue 1

Faculty:

John P. Leonard, MD Martin S. Tallman, MD Ann F. Mohrbacher, MD

Irene M. Ghobrial, MD Kenneth Anderson, MD Alessandra Ferrajoli, MD

Alexandra M. Levine, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

• Discuss recent data on the use of novel treatments and novel combinations therapies in frontline and relapsed/refractory multiple myeloma
• Discuss the implications of data on the use of targeted therapy in older patients with acute lymphoblastic leukemia
• Describe data from studies investigating the safety and tolerability of fludarabine-based chemotherapy in older patients with indolent lymphoid malignancies
• Recount the findings of studies investigating novel therapies, including monoclonal antibodies, proteasome inhibitors, and chemoradioimmunotherapy, in non-Hodgkin’s lymphoma subtypes

Topics covered include:

• Fludarabine-Based Chemotherapy in Older Patients With Indolent Lymphoproliferative Disorders
• Combination monoclonal antibody therapy for patients with relapsed/refractory B cell non-Hodgkin’s lymphoma
• Bortezomib Combined With Melphalan and Prednisone Active and Safe as Initial Treatment for Elderly Patients With Multiple Myeloma
• New Strategies for Older Adults With Ph+ Acute Lymphoblastic Leukemia
• Bortezomib Is Active With Predictable, Manageable Toxicity in Patients With Relapsed or Refractory Mantle Cell Lymphoma
• Chemoradioimmunotherapy as Initial Treatment for Indolent Non-Hodgkin’s Lymphoma
• Dexamethasone and Bortezomib Are Safe, Associated With Augmented Response in Relapsed/Refractory Multiple Myeloma Patients